ArticleFrontiers in medicine2026
Enhancing therapeutic outcomes in degenerative lumbar disc disease: a retrospective study on combined autologous PRP injection and celecoxib therapy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the therapeutic value of autologous platelet-rich plasma (PRP) injection in patients with degenerative lumbar disc disease (DLDD), and to evaluate its clinical efficacy in alleviating pain, improving lumbar function, modulating inflammatory responses, and enhancing quality of life. Methods: This retrospective study included 112 DLDD patients treated at our hospital from April 2023 to February 2025. According to the treatment received, patients were divided into two groups. The control group ( Results: The observation group demonstrated significantly superior overall efficacy compared with the control group (total effective rate: 94.96% vs. 82.14%, Conclusion: Combining autologous PRP injection with oral celecoxib provides short-term pain relief, functional improvement, and reduction of inflammatory responses in DLDD patients without significantly increasing adverse reactions. However, longer follow-up is required to determine the durability of these effects and the long-term clinical value of PRP-based treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.